Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

Completed · Early Phase 1

Conditions studied: Glioblastoma Multiforme

In brief

Blood samples will be obtained from newly diagnosed GBM patients treated with combined radiotherapy (RT), temozolomide (TMZ) and bevacizumab (BEV) at specific time points. The primary outcome is the shift in T reg cell fraction a defined by determining the proportion of CD4 cells that are CD4+ CD25.

Key facts

Study ID

NCT01091792

Run by

Dartmouth-Hitchcock Medical Center

People needed

13

Starts

2010-03-01

Expected to finish

2015-04-02

Last updated by the study team

2018-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven GBM
• Karnofsky status equal to or greater than 60%

You may not qualify if…

• Inadequately controlled hypertension
• Prior history of hypertension crisis or hypertensive encephalopathy
• History of stroke or transient ischemic attach within 12 months

Where it is running

• Dartmouth Hithcock Medcial Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.